Evidence map›Paper›PMID 26808627›Full record

ArticlePloS one2016

Assessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, Nigeria.

Chimere Obiora Agomo, Wellington Aghoghovwia Oyibo, Colin Sutherland, Rachael Hallet, Mary Oguike

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Prevalence of molecular markers associated withThe Pan African medical journal · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Polymorphism Analysis ofDiseases (Basel, Switzerland) · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Human Genetic Markers and Structural Prediction ofJournal of environmental and public health · 2018
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Chimere Obiora AgomoMalaria Research Laboratory, Nigerian Institute of Medical Research, Lagos, Nigeria.
Wellington Aghoghovwia OyiboANDI Centre of Excellence for Malaria Diagnosis/WHO/TDR/FIND Malaria Specimen Bank Site, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria.
Colin SutherlandDepartment of Immunology, London School of Tropical Medicine and Hygiene, London, United Kingdom.
Rachael HalletDepartment of Immunology, London School of Tropical Medicine and Hygiene, London, United Kingdom.
Mary OguikeDepartment of Immunology, London School of Tropical Medicine and Hygiene, London, United Kingdom.
London School of Hygiene & Tropical Medicine · GBNigerian Institute of Medical Research · NGUniversity of Lagos · NG

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThe use of antimalarial drugs for prevention and treatment is a major strategy in the prevention of malaria in pregnancy. Although sulphadoxine-pyrimethamine (SP) is currently recommended for intermittent preventive treatment of malaria during pregnancy in Nigeria, previously used drugs for prophylaxis such as chloroquine (CQ) and pyrimethamine are accessible as they are purchased over the counter. This study describes the markers of absence or presence of resistance to quinoline (Pfcrt and Pfmdr 1) and type 1 antifolate antimalarial medicines (Pfdhfr).

methodsPlasmodium falciparum-positive dried blood spots from pregnant women attending antenatal clinics for the first time during current pregnancy were investigated for the presence of mutations at codons 72-76 of Plasmodium falciparum chloroquine resistance transporter (Pfcrt) gene by real time polymerase chain reaction (PCR) using haplotype-specific probes. PCR followed by sequence analysis was used to identify mutations at codons 86, 184, 1034, 1042 and 1246 of P. falciparum multi-drug resistance-1 (Pfmdr1) gene; and codons 16, 50, 51, 59, 108, 140 and 164 of Pfdhfr gene.

resultsTwo haplotypes of Pfcrt (n = 54) were observed: CVMNK 13(24.2%) and CVIET 41 (75.9%) of the samples. The SVMNT haplotype was absent in this population. The Pfmdr1 (n = 28) haplotypes were NYSND 15(53.6%), YYSND 5(17.9%), NFSND 6(21.4%) and YFSND 2(7.1%). The Pfdhfr (n = 15) were ACNCSVI 4(26.7%), and ACICNSVI 1(6.7%) and ACIRNVI 10 (66.7%). The rate of occurrence of Pfcrt 76T, Pfdhfr108N, Pfmdr186Y and 184F were 75.9%, 73.3%, 25% and 28.1% respectively. The Pfmdr1 86Y was associated with low parasitaemia (median = 71 parasites/μl, P = 0.024) while Pfcrt 76T was associated with young maternal age (mean 24.1 ± 4.5 years; P = 0.006). The median parasitaemia were similar (P>0.05) in wild and mutant strains of Pfcrt 76, Pfmdr1 184 and Pfdhfr 108. There was no association between gravidity or gestational age of the women and presence of mutations in the Pfcrt, Pfmdr1 or Pfdhfr genes (P>0.05).

conclusionMarkers of resistance to chloroquine and pyrimethamine were high, whereas cycloguanil-resistance marker was not present in the studied population. The low level of mutations in the Pfmdr1gene indicates likely efficacy of amodiaquine against malaria in pregnancy.

Indexed as

AdultAntimalarialsDrug ResistanceFemaleHumansMalaria, FalciparumMembrane Transport ProteinsNigeriaPlasmodium falciparumPregnancyPregnancy ComplicationsPregnant PeopleProtozoan ProteinsQuinolinesYoung AdultAntimalarialsMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumProtozoan ProteinsquinolineQuinolines

Identifiers

PMID26808627
PMCPMC4726598
OpenAlexW2269168683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.